Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Pharmaceuticals Holding Co. is conducting a study titled ‘A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitor Combined With Endocrine Therapy.’ The study aims to evaluate the safety and efficacy of the drug SPH4336 when used alongside endocrine therapy for patients with advanced breast cancer, offering potential new treatment avenues for those who have not responded to previous therapies.
The intervention being tested involves SPH4336 tablets, which are administered orally, in combination with Letrozole tablets and Fulvestrant injections. This combination is intended to treat patients with specific types of breast cancer that have progressed despite prior treatment.
The study is designed as a randomized, double-blind trial with a parallel intervention model. Both participants and investigators are masked to the treatment allocations, ensuring unbiased results. The primary purpose of the study is treatment-focused, aiming to provide new insights into effective cancer therapies.
The study began on May 8, 2023, and is currently recruiting participants. The primary completion date is projected for August 15, 2025, which is also the date of the last update. These dates are crucial for tracking the study’s progress and anticipating future results.
This study update could influence Shanghai Pharmaceuticals’ stock performance positively, as successful outcomes may enhance their market position in the oncology sector. Investors should monitor developments closely, considering the competitive landscape of cancer treatment innovations.
The study is ongoing, with further details available on the ClinicalTrials portal.